AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Corporate Update (May 2020)

25 slides from AVEO Pharmaceuticals's corporate update, May 29, 2020

  1. Slide 1: TIVO-3 Overall Survival Update Conference Call

    Passionately pursuing a better life for patients with cancer TIVO-3 Overall Survival Update Conference Call May 29, 2020 Exhibit 99.1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained

  3. Slide 3: Introductions and Agenda

    Introductions Sumanta Kumar (Monty) Pal, M.D. Clinical Professor, Department of Medical Oncology & Therapeutics Research; Co-director, Kidney Cancer Program, City of Hope Cancer Center Michael Bailey, CEO Michael Needle, MD, CMO Erick Lucera, CFO Mike Ferraresso, SVP, Business Analytics and Commerci

  4. Slide 4: Final OS analysis of phase 3 TIVO-3 study

    TIVO-3: Final OS analysis of a phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC) May 29, 2020

  5. Slide 5: Clinical Context

    TIVO-3: Clinical Context The treatment of patients with renal cell carcinoma (RCC) has advanced with the advent of anti-angiogenic drugs known as vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR TKI) Tivozanib is a highly potent and selective VEGFR TKI with a long half-l

  6. Slide 6: Study Schema

    TIVO-3: Study Schema N = 350 Recurrent/metastatic RCC ECOG PS 0 or 1 Failed at least two prior regimens including VEGFR-TKI Stratified by IMDC and prior regimen (TKI-TKI; TKI-CPI; TKI-Other) RANDOMIZE 1:1 Endpoints Primary: PFS Secondary: OS, ORR, DoR, Safety and Tolerability for ITT Randomized Tria

  7. Slide 7: Patient Demographics

    TIVO-3: Patient Demographics Characteristic Tivozanib (N=175) Sorafenib (N=175) Median age, years 62 64 Male 72% 73% IMDC prognostic risk Favorable 19% 21% Intermediate 62% 60% Poor 18% 19% ECOG performance status (0/1) (49% / 50%) (47% / 48%) Region (NA/EU) (18% / 82%) (15% / 85%) Prior Lines of Th

  8. Slide 8: Met Primary Endpoint of PFS

    TIVO-3: Met Primary Endpoint of PFS Primary PFS endpoint final analyses, Oct 4, 2018 Tivozanib 170 128 94 69 56 48 37 31 24 20 16 14 6 0 0 Sorafenib 159 116 65 42 27 18 11 9 5 3 3 2 2 0 0 1 yr PFS 28% 11% 18% 5% Tivozanib Sorafenib Subjects at risk Tivozanib N=170 Sorafenib N=159 Median, months (95%

  9. Slide 9: Secondary Endpoint, ORR & DoR Statistically Significant Improvement vs Sorafenib

    TIVO-3: Secondary Endpoint, ORR & DoR Statistically Significant Improvement vs Sorafenib Tivozanib Sorafenib ORR 18% 8% ORR p-value 0.02 Median DoR Not reached (12.9, NR) 5.7 months (5.6, NR) % Change in Target Lesion Longest Diameter Sum Response rate final analyses, Oct 4, 2018

  10. Slide 10: Demonstrated Superior PFS & ORR in CPI Subgroup

    TIVO-3: Demonstrated Superior PFS & ORR in CPI Subgroup Prior Checkpoint Inhibitor (CPI) + VEGFR TKI Tivozanib (n=47) Sorafenib (n=44) Sorafenib (n=44) Median PFS months (95% CI) 7.3 (4.8, 11.1) 5.1 (3.2, 7.4) 5.1 (3.2, 7.4) HR (95% CI) 0.55 (0.32, 0.94) P-value 0.028 ORR 24.4% 6.8% Porta et al. ASC

  11. Slide 11: Treatment-Related Adverse Events

    TIVO-3: Treatment-Related Adverse Events TRAEs ≥ 20% frequency in either arm* Tivozanib (N=173)^ Sorafenib (N=170)^ Preferred Term All Grades % Grade 3/4 % All Grades % Grade 3/4 % Treatment Related AEs 84 46 94 55 Hypertension 38 21 25 14 Diarrhea 33 2 50 9 Fatigue 29 4 19 5 Decreased Appetite 27 4

  12. Slide 12: Dose Modifications

    TIVO-3: Dose Modifications Characteristic Tivozanib (N=173)^ Sorafenib (N=170)^ Mean Number of Cycles Initiated 11.9 6.7 AEs Leading to Dose Reductions (%) 25 39 AEs Leading to Dose Interruption (%) 50 64 ADRs Leading to Permanent Discontinuation (%) 8 15 Treatment Related SAEs (%) 12 11 Treatment R

  13. Slide 13: Final Overall Survival – May 2020

    Final Overall Survival – May 2020 Tivozanib N=175 Sorafenib N=175 Median OS, months 16.4 19.2 HR (95% CI) 0.97 (0.75–1.25) p-value Stratified Log-rank 0.82 Tivozanib Sorafenib

  14. Slide 14: Conclusions

    Conclusions In this final analysis of survival in the TIVO-3 trial, tivozanib demonstrated clinically meaningful and statistically significant improvement in PFS with similar OS in patients with highly relapsed or refractory metastatic RCC Patients treated with a prior CPI and VEGFR TKI or 2 VEGFR T

  15. Slide 15: Regulatory Update & Considerations

    Regulatory Update & Considerations

  16. Slide 16: Tivozanib New Drug Application

    Tivozanib New Drug Application FDA dialogue actively proceeding NDA filed for R/R RCC March 31, 2020 Final OS data submitted as last component of the NDA Application Orientation Meeting (AOM) completed NDA submission is based on the TIVO-3 trial and supported by three additional trials Active compar

  17. Slide 17: Positive Risk/Benefit Profile for Relapsed or Refractory RCC

    Positive Risk/Benefit Profile for Relapsed or Refractory RCC Limited evidence for sequencing therapies in highly refractory RCC or after treatment with a checkpoint inhibitor TIVO-3 provides first Phase 3 dataset in a 3rd and 4th line patient population First large randomized study to evaluate treat

  18. Slide 18: No VEGFR TKI Has Shown an OS Advantage Over Another in RCC

    No VEGFR TKI Has Shown an OS Advantage Over Another in RCC Note: Data from separate studies 1) Hutson et al. Clinical Genitourinary Cancer; Vol. 15, No. 1, 72-6. 2) Choueiri et al. European Journal of Cancer 2018; 94: 115e125 3) Motzer et. al. Lancet Oncol 2013; 14: 552–62. 4) Motzer, et al. N Engl

  19. Slide 19: Commercial Opportunity

    Commercial Opportunity A/=O ONCOLOGY C dfernalk

  20. Slide 20: Significant Potential Commercial Opportunity for Tivozanib in the United States

    If Approved, Significant Potential Commercial Opportunity for Tivozanib in the United States 2nd Line Market (est. 2020) ~$700M1 NA royalties to KHK are low- to mid-teens on net sales Extended OS from IO may expand population eligible for 3rd line treatment 2 1 >PFS with tivozanib may extend treatme

  21. Slide 21: Potential Relevance of Tivozanib in Refractory RCC

    Potential Relevance of Tivozanib in Refractory RCC Source: AVEO blinded Third-Party U.S. Oncologist Market Research using approximate TIVO-3 PFS and AE profile - Dec 2018 n=100 Treatments with proven efficacy are needed for patients who have failed 2 or more lines of treatment for RCC I prefer using

  22. Slide 22: Tivozanib Properties May Provide Advantages in Combination with IO Therapy

    Nakamura K et al. Cancer Res 2006;66:9134–9142. Pawlowski N et al. AACR 2013. Poster 3971. Hammers, Emerging VEGF-I/O Combinations, ASCO 2017 Tivozanib Properties May Provide Advantages in Combination with IO Therapy A Phase 1/2, Open-Label, Multi-Center Study of Tivozanib in Combination with Nivolu

  23. Slide 23: Summary

    Summary FDA dialogue actively proceeding NDA filed for R/R RCC March 31, 2020 Application Orientation Meeting (AOM) completed Tivozanib is well positioned for the changing R/R RCC landscape R/R RCC is a significant monotherapy market opportunity: $1b and growing TIVO-3 is the first positive Phase 3

  24. Slide 24: Q&A

    Q&A M=O ONCOLOGY

  25. Slide 25: TIVO-3 Overall Survival Update Conference Call

    Passionately pursuing a better life for patients with cancer TIVO-3 Overall Survival Update Conference Call May 29, 2020

AVEO Pharmaceuticals — Corporate Update (May 2020) on 6ix